Blocking the MIF cytokine family to improve cancer therapy

Romina Mora Barthelmess; Cecile Vincke; Benoit Stijlemans; Jo Van Ginderachter

Blocking the MIF cytokine family to improve cancer therapy

Romina Mora Barthelmess, Cecile Vincke, Benoit Stijlemans, Jo Van Ginderachter

Research output: Unpublished contribution to conference › Poster

Abstract

Macrophage Migration Inhibitory Factor (MIF) is a multifunctional cytokine, that upon binding to its main receptor, CD74, promotes angiogenesis, cell survival, and the expression of pro-inflammatory cytokines. This cytokine has been recognized as a biomarker of different autoimmune and cardiovascular diseases, metabolic disorders, systemic infections, and several types of cancer. The blockade of MIF by small synthetic compounds (ISO-1; ISO-66), or its genetic ablation in several cancer models resulted in a significant tumor reduction, confirming its pro-tumoral role. In this regard, our laboratory has identified anti-mouse/human MIF cross-reactive nanobodies (Nbs, i.e. recombinant variable domains of heavy-chain-only antibodies), that were able to prevent endotoxic shock in an experimental murine model. In addition, when used as a monotherapy, these anti-MIF Nbs significantly reduced the MC-38 colorectal cancer tumor growth by promoting an anti-tumoral immune response. Additionally, when combined with anti-PD-1 treatment, a superior tumor regression was observed compared to the use of anti-PD-1 monotherapy alone.
Finally, the tailorability of the Nbs could also facilitate the design of multivalent Nb constructs directed against MIF.

Original language	English
Publication status	Published - 19 Sep 2023
Event	The Single-Domain Antibodies 2023 meeting: 3rd congress on single-domain antibodies - CIS auditorium, Institut Pasteur, Paris, France Duration: 18 Sep 2023 → 20 Sep 2023 https://www.nanobodies2023.conferences-pasteur.org

Conference

Conference	The Single-Domain Antibodies 2023 meeting
Country/Territory	France
City	Paris
Period	18/09/23 → 20/09/23
Internet address	https://www.nanobodies2023.conferences-pasteur.org

Cite this

@conference{9179bcb01c694e11b4e4624be186ac7d,

title = "Blocking the MIF cytokine family to improve cancer therapy",

abstract = "Macrophage Migration Inhibitory Factor (MIF) is a multifunctional cytokine, that upon binding to its main receptor, CD74, promotes angiogenesis, cell survival, and the expression of pro-inflammatory cytokines. This cytokine has been recognized as a biomarker of different autoimmune and cardiovascular diseases, metabolic disorders, systemic infections, and several types of cancer. The blockade of MIF by small synthetic compounds (ISO-1; ISO-66), or its genetic ablation in several cancer models resulted in a significant tumor reduction, confirming its pro-tumoral role. In this regard, our laboratory has identified anti-mouse/human MIF cross-reactive nanobodies (Nbs, i.e. recombinant variable domains of heavy-chain-only antibodies), that were able to prevent endotoxic shock in an experimental murine model. In addition, when used as a monotherapy, these anti-MIF Nbs significantly reduced the MC-38 colorectal cancer tumor growth by promoting an anti-tumoral immune response. Additionally, when combined with anti-PD-1 treatment, a superior tumor regression was observed compared to the use of anti-PD-1 monotherapy alone. Finally, the tailorability of the Nbs could also facilitate the design of multivalent Nb constructs directed against MIF.",

author = "{Mora Barthelmess}, Romina and Cecile Vincke and Benoit Stijlemans and {Van Ginderachter}, Jo",

year = "2023",

month = sep,

day = "19",

language = "English",

note = "The Single-Domain Antibodies 2023 meeting : 3rd congress on single-domain antibodies ; Conference date: 18-09-2023 Through 20-09-2023",

url = "https://www.nanobodies2023.conferences-pasteur.org",

}

TY - CONF

T1 - Blocking the MIF cytokine family to improve cancer therapy

AU - Mora Barthelmess, Romina

AU - Vincke, Cecile

AU - Stijlemans, Benoit

AU - Van Ginderachter, Jo

PY - 2023/9/19

Y1 - 2023/9/19

N2 - Macrophage Migration Inhibitory Factor (MIF) is a multifunctional cytokine, that upon binding to its main receptor, CD74, promotes angiogenesis, cell survival, and the expression of pro-inflammatory cytokines. This cytokine has been recognized as a biomarker of different autoimmune and cardiovascular diseases, metabolic disorders, systemic infections, and several types of cancer. The blockade of MIF by small synthetic compounds (ISO-1; ISO-66), or its genetic ablation in several cancer models resulted in a significant tumor reduction, confirming its pro-tumoral role. In this regard, our laboratory has identified anti-mouse/human MIF cross-reactive nanobodies (Nbs, i.e. recombinant variable domains of heavy-chain-only antibodies), that were able to prevent endotoxic shock in an experimental murine model. In addition, when used as a monotherapy, these anti-MIF Nbs significantly reduced the MC-38 colorectal cancer tumor growth by promoting an anti-tumoral immune response. Additionally, when combined with anti-PD-1 treatment, a superior tumor regression was observed compared to the use of anti-PD-1 monotherapy alone. Finally, the tailorability of the Nbs could also facilitate the design of multivalent Nb constructs directed against MIF.

AB - Macrophage Migration Inhibitory Factor (MIF) is a multifunctional cytokine, that upon binding to its main receptor, CD74, promotes angiogenesis, cell survival, and the expression of pro-inflammatory cytokines. This cytokine has been recognized as a biomarker of different autoimmune and cardiovascular diseases, metabolic disorders, systemic infections, and several types of cancer. The blockade of MIF by small synthetic compounds (ISO-1; ISO-66), or its genetic ablation in several cancer models resulted in a significant tumor reduction, confirming its pro-tumoral role. In this regard, our laboratory has identified anti-mouse/human MIF cross-reactive nanobodies (Nbs, i.e. recombinant variable domains of heavy-chain-only antibodies), that were able to prevent endotoxic shock in an experimental murine model. In addition, when used as a monotherapy, these anti-MIF Nbs significantly reduced the MC-38 colorectal cancer tumor growth by promoting an anti-tumoral immune response. Additionally, when combined with anti-PD-1 treatment, a superior tumor regression was observed compared to the use of anti-PD-1 monotherapy alone. Finally, the tailorability of the Nbs could also facilitate the design of multivalent Nb constructs directed against MIF.

M3 - Poster

T2 - The Single-Domain Antibodies 2023 meeting

Y2 - 18 September 2023 through 20 September 2023

ER -